Take-Home Supply Of Buprenorphine (oral); Up To 7 Additional Day Supply (provision Of The Services By A Medicare-Enrolled Opioid Treatment Program); List Separately In Addition To Code For Primary Procedure in Texas

Texas Pricing in Context

In Texas, CPT code G2079 (Take-Home Supply Of Buprenorphine (oral); Up To 7 Additional Day Supply (provision Of The Services By A Medicare-Enrolled Opioid Treatment Program); List Separately In Addition To Code For Primary Procedure) carries an average Medicare payment of $77.76 — 0% below the national benchmark of $77.85. 15 providers across the state submitted claims for this procedure in 2023, performing 320 total services. Individual payments in TX ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Texas is $160.84, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Texas sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Temporary Procedures procedures, the estimated commercial insurance price in Texas lands near $181.57, with self-pay cash prices typically around $103.44. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.